---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-025167"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-07-31T12:00:12+00:00"
generated_at: "2026-07-31T12:05:26.702897+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports 37% blinded CRc in MIRACLE trial; venetoclax-failed subgroup similar

## Summary
- Preliminary blinded CRc of 37% and CR of 24% in 62 evaluable R/R AML subjects.
- Among 30 patients who failed prior venetoclax, CRc also 37% (3x published salvage rate of ~13%).
- No cardiotoxicity observed; enrollment at 74 of 90; final Part A treatment expected Sept 2026.
- Unblinded Part A results expected Dec 2026–Feb 2027; prior unblinded Annamycin arms showed CRc 50-57% vs control 29%.

## SEC filing metadata
- accession: 0001437749-26-025167
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-07-31T12:00:12+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926025167/0001437749-26-025167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926025167/mbrx20260729_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-025167
- JSON: https://secwatch.observer/filing/0001437749-26-025167.json
- Plain text: https://secwatch.observer/filing/0001437749-26-025167.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.